Literature DB >> 19728903

[Epidemiologic trend of and strategies for colorectal cancer].

De-Sen Wan1.   

Abstract

The incidence and mortality of colorectal cancer (CRC) show increasing tendency worldwide. It was predicted that the new cases in 2007 would be approximate 1,200,000 and the death cases would be 630,000, a total increase of 27% and 28% and an annual increase of 3.9% and 4.0%, respectively, compared with the figures in 2000. In addition, the incidence of CRC varies regionally and changes over the time. In previously identified high-incidence areas, there are three tendencies: one is to keep rising such as in UK, one is to be stable such as in New Zealand, and the third one is to decrease such as in US and Western Europe. In previously identified low-incidence areas, the incidence of CRC is increasing, such as in Japan, Hong Kong, Singapore, Hungary, Poland, Israel, and Puerto-Rico, especially in Japan, where the incidence increases the fastest. Similarly, the incidence of CRC is increased by 4.2% annually in Shanghai, China, which is faster than the average increasing rate of the world. Since 1991, the average increase in mortality of CRC is 4.7% every year. The increasing number of female patients and the shift of the tumor location to the right side are also noticed for CRC in recent years. We summarized that CRC is a disease caused by synergism of environment and diet, life style and heredity. It was suggested that CRC can be prevented effectively through developing a regular life style, having proper diet, actively participating in the screening for cancers, and removing the pre-cancer lesions.

Entities:  

Mesh:

Year:  2009        PMID: 19728903     DOI: 10.5732/cjc.008.10833

Source DB:  PubMed          Journal:  Ai Zheng


  21 in total

Review 1.  Role of phytochemicals in colorectal cancer prevention.

Authors:  Yu-Hua Li; Yin-Bo Niu; Yang Sun; Feng Zhang; Chang-Xu Liu; Lei Fan; Qi-Bing Mei
Journal:  World J Gastroenterol       Date:  2015-08-21       Impact factor: 5.742

2.  Correlation of aberrant expression of CD133 with FHIT and malignant phenotype of colorectal adenocarcinoma.

Authors:  Hong Li; Po Zhao; Yang Lu; Yali Lu
Journal:  Int J Colorectal Dis       Date:  2012-02-09       Impact factor: 2.571

3.  Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study.

Authors:  Ting Deng; Le Zhang; Xiao-jian Liu; Jian-ming Xu; Yu-xian Bai; Yan Wang; Yu Han; Yu-hong Li; Yi Ba
Journal:  Med Oncol       Date:  2013-10-31       Impact factor: 3.064

4.  Higher intake of carotenoid is associated with a lower risk of colorectal cancer in Chinese adults: a case-control study.

Authors:  Min-Shan Lu; Yu-Jing Fang; Yu-Ming Chen; Wei-Ping Luo; Zhi-Zhong Pan; Xiao Zhong; Cai-Xia Zhang
Journal:  Eur J Nutr       Date:  2014-07-22       Impact factor: 5.614

5.  Polymorphisms in TP53 and MDM2 contribute to higher risk of colorectal cancer in Chinese population: a hospital-based, case-control study.

Authors:  Yuxing Zhang; Li Liu; Yingchun Tang; Chao Chen; Qian Wang; Jun Xu; Chao Yang; Xiaoping Miao; Sheng Wei; Jigui Chen; Shaofa Nie
Journal:  Mol Biol Rep       Date:  2012-06-29       Impact factor: 2.316

6.  Characteristics of colorectal tumours in asymptomatic patients with negative immunochemical faecal occult blood test results.

Authors:  Kunihiko Wakamura; Shin-Ei Kudo; Hideyuki Miyachi; Kenta Kodama; Seiko Hayashi; Yasuharu Maeda; Yushi Ogawa; Yuta Kouyama; Shin-Ichi Kataoka; Kazuki Kato; Katsuro Ichimasa; Masashi Misawa; Yuichi Mori; Toyoki Kudo; Takemasa Hayashi; Fumio Ishida; Shogo Ohkoshi
Journal:  Mol Clin Oncol       Date:  2015-07-01

7.  Combining bevacizumab and panitumumab with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as second-line treatment in patients with metastatic colorectal cancer.

Authors:  Hong-Liang Liang; Ai-Ping Hu; Sen-Lin Li; Ji-Yong Liu
Journal:  Med Oncol       Date:  2014-05-03       Impact factor: 3.064

8.  Downregulation of mir-23b in plasma is associated with poor prognosis in patients with colorectal cancer.

Authors:  Chang-Hua Kou; Tian Zhou; Xi-Lin Han; Hui-Jie Zhuang; Hai-Xin Qian
Journal:  Oncol Lett       Date:  2016-10-14       Impact factor: 2.967

9.  MicroRNA-139-3p indicates a poor prognosis of colon cancer.

Authors:  Xiaojing Liu; Bensong Duan; Yuanyuan Dong; Chengzhi He; Hongmei Zhou; Haihui Sheng; Hengjun Gao; Xizhi Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

10.  Prognostic value of miR-221-3p, miR-342-3p and miR-491-5p expression in colon cancer.

Authors:  Kun Tao; Jing Yang; Zhenhua Guo; Yuemei Hu; Haihui Sheng; Hengjun Gao; Hongyu Yu
Journal:  Am J Transl Res       Date:  2014-07-18       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.